journal article·2025-12-28

Photoactivatable DNA Conveyer Ferries Cellular Receptors to Lysosome for Collaborative Degradation in Zebrafish

Shan Chen, Yufei Zhuo, Liying Pang, Hong Liang, Xiahui Lin, Jingying Li

Publisher page

Abstract

Targeted protein degradation (TPD) offers significant potential for modulating disease-driving receptor functions in vivo as an antitumor strategy. However, mitigating off-target effects and enhancing therapeutic efficacy within the complex tumor microenvironment remain critical challenges. Herein, we introduce a photoactivatable DNA conveyer (PhoDC) designed for the collaborative degradation of two functionally linked receptors with high spatiotemporal resolution in vivo . This strategy utilizes an exogenous light signal to trigger a conformational switch in the DNA conveyer. Upon activation, PhoDC captures and ferries the dual-targeted receptors from the cell membrane to the lysosome for simultaneous degradation. This approach effectively achieved concurrent downregulation of the target receptors and suppressed tumor growth in a zebrafish xenograft model with precise controllability. By leveraging modular and versatile aptameric nucleic acids, the PhoDC platform offers improved safety and efficacy for cellular receptor degradation while circumventing complicated synthesis procedures. Therefore, this photoactivatable DNA conveyer holds considerable promise for advancing the development of precision cancer therapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Protein Degradation and Inhibitors · Click Chemistry and Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Geography and Oceanography, Fuzhou Institute of Oceanography

Minjiang University

MOE Key Laboratory for Analytical Science of Food Safety and Biology, Fujian Provincial Key Laboratory of Analysis and Detection Technology for Food Safety, College of Chemistry

Fuzhou University

College of Biological Science and Engineering

School of Medical Imaging

Fujian Medical University

Funding

National Key Research and Development Program of China · Natural Science Foundation of Fujian Province · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1136/mp.53.6.29510.1136/mp.53.6.295 ↗
2. 10.1021/jacs.2c1042810.1021/jacs.2c10428 ↗
3. 10.1007/s00726-021-02991-z10.1007/s00726-021-02991-z ↗
4. 10.3390/cancers703086010.3390/cancers7030860 ↗
5. 10.1038/s41587-022-01456-210.1038/s41587-022-01456-2 ↗
6. 10.1021/jacs.4c0479410.1021/jacs.4c04794 ↗
7. 10.1002/anie.20210132810.1002/anie.202101328 ↗
8. 10.1016/j.apsb.2020.01.01410.1016/j.apsb.2020.01.014 ↗
9. 10.1021/jacs.2c0836710.1021/jacs.2c08367 ↗
10. 10.1038/s41586-022-05235-610.1038/s41586-022-05235-6 ↗
11. 10.1021/jacs.0c1000810.1021/jacs.0c10008 ↗
12. 10.1002/anie.20210217010.1002/anie.202102170 ↗
13. 10.1002/smll.20231003910.1002/smll.202310039 ↗
14. 10.1021/acscentsci.1c0014610.1021/acscentsci.1c00146 ↗
15. 10.1002/anie.20210399310.1002/anie.202103993 ↗
16. 10.1002/advs.20241077810.1002/advs.202410778 ↗
17. 10.1021/jacs.9b0642210.1021/jacs.9b06422 ↗
18. 10.1016/j.chembiol.2021.05.01010.1016/j.chembiol.2021.05.010 ↗
19. 10.1016/j.bioorg.2023.10705010.1016/j.bioorg.2023.107050 ↗
20. 10.1021/acscentsci.9b0071310.1021/acscentsci.9b00713 ↗
21. 10.1021/jacs.1c0432410.1021/jacs.1c04324 ↗
22. 10.1016/j.ejmech.2021.11360810.1016/j.ejmech.2021.113608 ↗
23. 10.1021/jacs.3c1123210.1021/jacs.3c11232 ↗
24. 10.1002/chem.20180386810.1002/chem.201803868 ↗
25. 10.1021/acs.jmedchem.2c0155710.1021/acs.jmedchem.2c01557 ↗
26. 10.1002/anie.20190897110.1002/anie.201908971 ↗
27. 10.1002/anie.20200356310.1002/anie.202003563 ↗
28. 10.1002/anie.20220845110.1002/anie.202208451 ↗
29. 10.1016/j.omtn.2022.09.00810.1016/j.omtn.2022.09.008 ↗
30. 10.1002/advs.20230963910.1002/advs.202309639 ↗
31. 10.1073/pnas.130259411010.1073/pnas.1302594110 ↗
32. 10.1021/acs.nanolett.9b0132010.1021/acs.nanolett.9b01320 ↗
33. 10.1021/jacs.3c0389910.1021/jacs.3c03899 ↗
34. 10.1002/anie.20242512310.1002/anie.202425123 ↗
35. 10.1021/jacs.4c1001010.1021/jacs.4c10010 ↗
36. 10.1002/anie.20211379510.1002/anie.202113795 ↗
37. 10.1073/pnas.142010511110.1073/pnas.1420105111 ↗
38. 10.1172/JCI3604910.1172/JCI36049 ↗
39. 10.1158/0008-5472.CAN-07-596210.1158/0008-5472.CAN-07-5962 ↗
40. 10.1021/acs.molpharmaceut.8b0038810.1021/acs.molpharmaceut.8b00388 ↗
41. 10.1021/jacs.2c1382510.1021/jacs.2c13825 ↗
42. 10.31635/ccschem.023.20230294210.31635/ccschem.023.202302942 ↗
43. 10.1016/j.cej.2025.16197410.1016/j.cej.2025.161974 ↗
44. 10.1091/mbc.e04-07-056710.1091/mbc.e04-07-0567 ↗
45. 10.1074/jbc.M111.23826110.1074/jbc.M111.238261 ↗
46. Martens T. · Clin. Cancer Res. · 2006 · 12 · 614410.1158/1078-0432.CCR-05-1418 ↗
47. 10.1186/1471-2407-13-8310.1186/1471-2407-13-83 ↗
48. 10.1186/s12885-022-10136-y10.1186/s12885-022-10136-y ↗
49. 10.1007/s10120-020-01139-410.1007/s10120-020-01139-4 ↗
50. 10.1016/j.cell.2010.06.01110.1016/j.cell.2010.06.011 ↗